[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fx7lwMKEAczu4Cq8MFkU5n7qbLKWI85wJk7R-npNw6Qk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":33,"phaseBuckets":39,"rows":46},"Manchester University NHS Foundation Trust",[4],138,false,20,2,76590,121,[13,16,19,22,24,27,29,31],{"name":14,"count":15},"Diabetes Mellitus, Type 1",6,{"name":17,"count":18},"Breast Cancer",5,{"name":20,"count":21},"Heart Failure",4,{"name":23,"count":21},"Asthma",{"name":25,"count":26},"Sepsis",3,{"name":28,"count":26},"Chronic Cough",{"name":30,"count":26},"Cardiovascular Diseases",{"name":32,"count":9},"Childhood Cancer",[34],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05653193","Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study","2026-11","Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care",[40,41,42,43,44,45],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[47,74,92,118,145,163,188,206,234,252,280,298,323,349,374,408,433,461,485,512,536],{"intervention":38,"totalTrials":48,"cells":49},1,{"EARLY_PHASE1":50,"PHASE1":53,"PHASE2":55,"PHASE3":68,"PHASE4":70,"NA":72},{"trials":51,"activeCount":52},[],0,{"trials":54,"activeCount":52},[],{"trials":56,"activeCount":48,"soonestReadout":37},[57],{"nctId":35,"briefTitle":36,"status":58,"phases":59,"primaryCompletion":37,"completion":60,"start":61,"enrollment":62,"conditions":63,"interventions":66},"RECRUITING",[42],"2026-12","2024-05-17",50,[64,65],"Chronic Pulmonary Aspergillosis","Aspergillosis",[38,67],"Antifungals as standard of care",{"trials":69,"activeCount":52},[],{"trials":71,"activeCount":52},[],{"trials":73,"activeCount":52},[],{"intervention":67,"totalTrials":48,"cells":75},{"EARLY_PHASE1":76,"PHASE1":78,"PHASE2":80,"PHASE3":86,"PHASE4":88,"NA":90},{"trials":77,"activeCount":52},[],{"trials":79,"activeCount":52},[],{"trials":81,"activeCount":48,"soonestReadout":37},[82],{"nctId":35,"briefTitle":36,"status":58,"phases":83,"primaryCompletion":37,"completion":60,"start":61,"enrollment":62,"conditions":84,"interventions":85},[42],[64,65],[38,67],{"trials":87,"activeCount":52},[],{"trials":89,"activeCount":52},[],{"trials":91,"activeCount":52},[],{"intervention":93,"totalTrials":48,"cells":94},"nicotinic acid\u002Flaropiprant",{"EARLY_PHASE1":95,"PHASE1":97,"PHASE2":99,"PHASE3":101,"PHASE4":103,"NA":116},{"trials":96,"activeCount":52},[],{"trials":98,"activeCount":52},[],{"trials":100,"activeCount":52},[],{"trials":102,"activeCount":52},[],{"trials":104,"activeCount":52},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":115},"NCT01054508","Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers","COMPLETED",[44],"2012-01","2010-06",38,[114],"Hypercholesterolemia",[93],{"trials":117,"activeCount":52},[],{"intervention":119,"totalTrials":48,"cells":120},"Transdermal testosterone gel",{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":129,"NA":143},{"trials":122,"activeCount":52},[],{"trials":124,"activeCount":52},[],{"trials":126,"activeCount":52},[],{"trials":128,"activeCount":52},[],{"trials":130,"activeCount":52},[131],{"nctId":132,"briefTitle":133,"status":108,"phases":134,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":141},"NCT00190060","Study of The Effects of Testosterone in Frail Elderly Men",[44],"2008-12-31","2004-10",262,[139,140],"Frailty","Sarcopenia",[119,142],"Matched transdermal placebo gel",{"trials":144,"activeCount":52},[],{"intervention":142,"totalTrials":48,"cells":146},{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":153,"PHASE4":155,"NA":161},{"trials":148,"activeCount":52},[],{"trials":150,"activeCount":52},[],{"trials":152,"activeCount":52},[],{"trials":154,"activeCount":52},[],{"trials":156,"activeCount":52},[157],{"nctId":132,"briefTitle":133,"status":108,"phases":158,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":159,"interventions":160},[44],[139,140],[119,142],{"trials":162,"activeCount":52},[],{"intervention":164,"totalTrials":48,"cells":165},"10 % Lidocaine",{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":170,"PHASE3":172,"PHASE4":174,"NA":186},{"trials":167,"activeCount":52},[],{"trials":169,"activeCount":52},[],{"trials":171,"activeCount":52},[],{"trials":173,"activeCount":52},[],{"trials":175,"activeCount":52},[176],{"nctId":177,"briefTitle":178,"status":108,"phases":179,"primaryCompletion":180,"completion":180,"start":181,"enrollment":182,"conditions":183,"interventions":184},"NCT01252225","Lidocaine: Effect of Lidocaine in Chronic Cough",[44],"2011-05","2011-02",30,[28],[164,164,185],"0.9% saline",{"trials":187,"activeCount":52},[],{"intervention":185,"totalTrials":48,"cells":189},{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":196,"PHASE4":198,"NA":204},{"trials":191,"activeCount":52},[],{"trials":193,"activeCount":52},[],{"trials":195,"activeCount":52},[],{"trials":197,"activeCount":52},[],{"trials":199,"activeCount":52},[200],{"nctId":177,"briefTitle":178,"status":108,"phases":201,"primaryCompletion":180,"completion":180,"start":181,"enrollment":182,"conditions":202,"interventions":203},[44],[28],[164,164,185],{"trials":205,"activeCount":52},[],{"intervention":207,"totalTrials":48,"cells":208},"Paracetamol",{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":213,"PHASE3":215,"PHASE4":230,"NA":232},{"trials":210,"activeCount":52},[],{"trials":212,"activeCount":52},[],{"trials":214,"activeCount":52},[],{"trials":216,"activeCount":52},[217],{"nctId":218,"briefTitle":219,"status":220,"phases":221,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":228},"NCT04986839","PAIR (Paracetamol and Ibuprofen Research) Pilot Trial","UNKNOWN",[42,43],"2023-12-01","2024-01-01","2021-09-03",32,[227],"Patent Ductus Arteriosus",[207,229],"Ibuprofen",{"trials":231,"activeCount":52},[],{"trials":233,"activeCount":52},[],{"intervention":229,"totalTrials":48,"cells":235},{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":242,"PHASE4":248,"NA":250},{"trials":237,"activeCount":52},[],{"trials":239,"activeCount":52},[],{"trials":241,"activeCount":52},[],{"trials":243,"activeCount":52},[244],{"nctId":218,"briefTitle":219,"status":220,"phases":245,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":246,"interventions":247},[42,43],[227],[207,229],{"trials":249,"activeCount":52},[],{"trials":251,"activeCount":52},[],{"intervention":253,"totalTrials":48,"cells":254},"hyperoncotic human albumin solution",{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":261,"PHASE4":276,"NA":278},{"trials":256,"activeCount":52},[],{"trials":258,"activeCount":52},[],{"trials":260,"activeCount":52},[],{"trials":262,"activeCount":52},[263],{"nctId":264,"briefTitle":265,"status":108,"phases":266,"primaryCompletion":267,"completion":268,"start":269,"enrollment":270,"conditions":271,"interventions":274},"NCT05208242","Strong Albumin Solutions in Patients With Septic Shock",[42,43],"2025-04-05","2026-01-31","2023-11-10",47,[25,272,273],"Septic Shock","Shock, Toxic",[253,275],"Buffered crystalloid solutions",{"trials":277,"activeCount":52},[],{"trials":279,"activeCount":52},[],{"intervention":275,"totalTrials":48,"cells":281},{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":288,"PHASE4":294,"NA":296},{"trials":283,"activeCount":52},[],{"trials":285,"activeCount":52},[],{"trials":287,"activeCount":52},[],{"trials":289,"activeCount":52},[290],{"nctId":264,"briefTitle":265,"status":108,"phases":291,"primaryCompletion":267,"completion":268,"start":269,"enrollment":270,"conditions":292,"interventions":293},[42,43],[25,272,273],[253,275],{"trials":295,"activeCount":52},[],{"trials":297,"activeCount":52},[],{"intervention":299,"totalTrials":48,"cells":300},"ulipristal acetate",{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":317,"PHASE4":319,"NA":321},{"trials":302,"activeCount":52},[],{"trials":304,"activeCount":52},[],{"trials":306,"activeCount":52},[307],{"nctId":308,"briefTitle":309,"status":108,"phases":310,"primaryCompletion":311,"completion":312,"start":313,"enrollment":314,"conditions":315,"interventions":316},"NCT02408770","Breast Cancer - Anti-Progestin Prevention Study 1",[42],"2019-03-18","2023-01-25","2016-01-22",24,[17],[299],{"trials":318,"activeCount":52},[],{"trials":320,"activeCount":52},[],{"trials":322,"activeCount":52},[],{"intervention":324,"totalTrials":48,"cells":325},"Trientine",{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":343,"PHASE4":345,"NA":347},{"trials":327,"activeCount":52},[],{"trials":329,"activeCount":52},[],{"trials":331,"activeCount":52},[332],{"nctId":333,"briefTitle":334,"status":108,"phases":335,"primaryCompletion":336,"completion":337,"start":338,"enrollment":339,"conditions":340,"interventions":342},"NCT04706429","The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy",[42],"2024-04-30","2024-07-30","2020-12-01",154,[341],"Hypertrophic Cardiomyopathy",[324],{"trials":344,"activeCount":52},[],{"trials":346,"activeCount":52},[],{"trials":348,"activeCount":52},[],{"intervention":350,"totalTrials":48,"cells":351},"Enalapril Maleate",{"EARLY_PHASE1":352,"PHASE1":354,"PHASE2":356,"PHASE3":368,"PHASE4":370,"NA":372},{"trials":353,"activeCount":52},[],{"trials":355,"activeCount":52},[],{"trials":357,"activeCount":52},[358],{"nctId":359,"briefTitle":360,"status":108,"phases":361,"primaryCompletion":362,"completion":362,"start":363,"enrollment":364,"conditions":365,"interventions":367},"NCT03466333","Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia",[42],"2020-09-11","2018-09-05",118,[30,366],"Pre-Eclampsia Onset Less Than 37 Weeks (Diagnosis)",[350],{"trials":369,"activeCount":52},[],{"trials":371,"activeCount":52},[],{"trials":373,"activeCount":52},[],{"intervention":375,"totalTrials":9,"cells":376},"Pirfenidone",{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":394,"PHASE4":396,"NA":398},{"trials":378,"activeCount":52},[],{"trials":380,"activeCount":52},[],{"trials":382,"activeCount":52},[383],{"nctId":384,"briefTitle":385,"status":108,"phases":386,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":393},"NCT02932566","The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction",[42],"2019-11-29","2020-04-29","2017-03-02",129,[392],"Cardiac Failure",[375],{"trials":395,"activeCount":52},[],{"trials":397,"activeCount":52},[],{"trials":399,"activeCount":52},[400],{"nctId":401,"briefTitle":402,"status":108,"phases":403,"primaryCompletion":387,"completion":388,"start":389,"enrollment":404,"conditions":405,"interventions":407},"NCT05826821","Biomarkers in HF: Circulating Biomarkers of Fibrosis and Cardiovascular Disease",[],107,[406],"Heart Failure With Preserved Ejection Fraction",[375],{"intervention":409,"totalTrials":48,"cells":410},"Standard Care Arm",{"EARLY_PHASE1":411,"PHASE1":413,"PHASE2":415,"PHASE3":417,"PHASE4":419,"NA":421},{"trials":412,"activeCount":52},[],{"trials":414,"activeCount":52},[],{"trials":416,"activeCount":52},[],{"trials":418,"activeCount":52},[],{"trials":420,"activeCount":52},[],{"trials":422,"activeCount":52},[423],{"nctId":424,"briefTitle":425,"status":108,"phases":426,"primaryCompletion":427,"completion":427,"start":428,"enrollment":429,"conditions":430,"interventions":432},"NCT04918758","Endoscopically-delivered Purastat to Treat Bleeding Caused by Radiation Proctopathy",[45],"2024-12-31","2021-07-22",26,[431],"Radiation Proctopathy",[409],{"intervention":434,"totalTrials":48,"cells":435},"Isansys Patient Status Engine",{"EARLY_PHASE1":436,"PHASE1":438,"PHASE2":440,"PHASE3":442,"PHASE4":444,"NA":446},{"trials":437,"activeCount":52},[],{"trials":439,"activeCount":52},[],{"trials":441,"activeCount":52},[],{"trials":443,"activeCount":52},[],{"trials":445,"activeCount":52},[],{"trials":447,"activeCount":52},[448],{"nctId":449,"briefTitle":450,"status":220,"phases":451,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":455,"interventions":460},"NCT05099237","Enhanced Monitoring for Better Recovery and Cancer Experience in Greater Manchester",[45],"2023-12-31","2021-12-01",80,[456,457,458,459],"Colorectal Cancer","Lung Cancer","Hematological Cancer","CAR T-Cell Therapy",[434],{"intervention":462,"totalTrials":48,"cells":463},"Pentoxifylline",{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":470,"PHASE4":472,"NA":474},{"trials":465,"activeCount":52},[],{"trials":467,"activeCount":52},[],{"trials":469,"activeCount":52},[],{"trials":471,"activeCount":52},[],{"trials":473,"activeCount":52},[],{"trials":475,"activeCount":52},[476],{"nctId":477,"briefTitle":478,"status":108,"phases":479,"primaryCompletion":480,"completion":480,"start":481,"enrollment":182,"conditions":482,"interventions":484},"NCT00315679","A Trial of Pentoxifylline for the Treatment of Recurrent Aphthous Stomatitis",[45],"1998-11","1996-06",[483],"Recurrent Aphthous Stomatitis",[462],{"intervention":486,"totalTrials":48,"cells":487},"integrated information and nurse led telephone clinic",{"EARLY_PHASE1":488,"PHASE1":490,"PHASE2":492,"PHASE3":494,"PHASE4":496,"NA":498},{"trials":489,"activeCount":52},[],{"trials":491,"activeCount":52},[],{"trials":493,"activeCount":52},[],{"trials":495,"activeCount":52},[],{"trials":497,"activeCount":52},[],{"trials":499,"activeCount":52},[500],{"nctId":501,"briefTitle":502,"status":108,"phases":503,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":508,"interventions":511},"NCT04244123","Web-based Adherence Information Integrated Nurse-led Monitoring Clinic",[],"2021-12-13","2023-01-05","2020-01-24",43,[509,510],"Short Stature","Growth Hormone Treatment",[486],{"intervention":513,"totalTrials":48,"cells":514},"Migalastat",{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":521,"PHASE4":523,"NA":525},{"trials":516,"activeCount":52},[],{"trials":518,"activeCount":52},[],{"trials":520,"activeCount":52},[],{"trials":522,"activeCount":52},[],{"trials":524,"activeCount":52},[],{"trials":526,"activeCount":52},[527],{"nctId":528,"briefTitle":529,"status":220,"phases":530,"primaryCompletion":452,"completion":452,"start":531,"enrollment":532,"conditions":533,"interventions":535},"NCT03949920","A Study of Migalastat in Fabry Disease",[],"2019-05-16",21,[534],"Fabry Disease",[513],{"intervention":537,"totalTrials":48,"cells":538},"Lispro",{"EARLY_PHASE1":539,"PHASE1":541,"PHASE2":543,"PHASE3":545,"PHASE4":547,"NA":549},{"trials":540,"activeCount":52},[],{"trials":542,"activeCount":52},[],{"trials":544,"activeCount":52},[],{"trials":546,"activeCount":52},[],{"trials":548,"activeCount":52},[],{"trials":550,"activeCount":52},[551],{"nctId":552,"briefTitle":553,"status":220,"phases":554,"primaryCompletion":555,"completion":555,"start":556,"enrollment":429,"conditions":557,"interventions":558},"NCT05660941","Automated Fully Closed-Loop Insulin Delivery in Type 1 Diabetes With Ultra-Rapid Lispro (ACOLYTE Study)",[45],"2024-05-01","2023-07-21",[14],[537,537]]